Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neurocrine Biosciences (NBIX)

Neurocrine Q4 net product sales up 29% to $798.3 million; 2026 INGREZZA guidance set

Positive Impact 3 of 5 earnings Written later

Neurocrine Biosciences reported fourth-quarter 2025 total revenues of $805.5 million, up from $627.7 million a year earlier, and GAAP diluted earnings per share of $1.48, up from $1.00. It also gave 2026 full-year guidance for INGREZZA net product sales of $2.7 billion to $2.8 billion, compared with $2.51 billion in 2025, which gives shareholders a revenue benchmark for the year ahead.

Key points

  • Q4 2025 total revenues were $805.5 million versus $627.7 million in Q4 2024; GAAP net income was $153.7 million versus $103.1 million.
  • Full-year 2025 net product sales were $2.83 billion, up 22%; CRENESSITY net product sales were $301.2 million versus $1.7 million in 2024.
  • 2026 guidance: INGREZZA net product sales of $2.7 billion to $2.8 billion; GAAP R&D expense of $1.2 billion to $1.25 billion; GAAP SG&A expense of $1.375 billion to $1.4 billion.
  • Cash, cash equivalents, and marketable securities totaled approximately $2.54 billion at December 31, 2025.

The filing

CompanyNeurocrine Biosciences (NBIX)
Form8-K, current report
Filed with the SECFeb 11, 2026, 4:02 PM ET
Accession number0000914475-26-000006

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.